Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anna Nieves

Nurse Practitioner, Primary Care Basking Ridge, NJ Nurse Practitioner

NPI 1477002343 CMS profile 11023208

131 Morristown Road, Basking Ridge, NJ 07920

Open in the dashboard

General payments

$7,082

405 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Nieves of Basking Ridge, NJ is reported in the CMS Open Payments database as having received $7,082 across 405 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,615 68
2024 General $1,863 86
2023 General $1,271 67
2022 General $1,461 105
2021 General $872 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Nieves
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Anna Nieves were reported at $1,615. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Anna Nieves Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $872 $137 $39–$445 $132
2022 $1,461 $139 $44–$421 $149
2023 $1,271 $163 $53–$481 $160
2024 $1,863 $176 $54–$511 $164
2025 $1,615 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,390 81 payments
  2. Janssen Biotech, Inc. $1,241 89 payments
  3. QOL Medical, LLC $737 43 payments
  4. E.R. Squibb & Sons, L.L.C. $658 6 payments
  5. Celgene Corporation $534 65 payments
  6. Ironwood Pharmaceuticals, Inc $348 21 payments
  7. Lilly USA, LLC $268 13 payments
  8. Phathom Pharmaceuticals, Inc. $260 12 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $207 14 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $204 7 payments
  11. Other $1,234 54 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,082 405 payments
Products named General payments · program years 2021–2025
  1. ZEPOSIA $934 68 payments
  2. STELARA $892 73 payments
  3. Sucraid $440 21 payments
  4. SKYRIZI Immunology $422 15 payments
  5. TREMFYA $395 20 payments
  6. RINVOQ $373 30 payments
  7. Linzess $348 21 payments
  8. SKYRIZI Immunology $345 18 payments
  9. CREON $319 23 payments
  10. OMVOH $250 12 payments
  11. Other $3,110 178 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

565

Median for Nurse Practitioner: 389

Drug cost

$465,087

Median for Nurse Practitioner: $21,885

Branded share of claims

14.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 16 $440,884
Linzess Linaclotide Brand 11 $9,914
Mesalamine Generic 11 $5,651
Famotidine Generic 133 $2,031
Pantoprazole Sodium Generic 134 $1,599
Rabeprazole Sodium Generic 24 $846
Lansoprazole Generic 18 $843
Omeprazole Generic 46 $715
Esomeprazole Magnesium Generic 26 $638
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 17 $404

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$15,902

Of which drugs: $25

Medicare patients

208

Average age 73

Services billed

339

118 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 38%
Ischemic heart disease 31%
Depression 22%
Cancer 21%
Osteoporosis 20%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution, 250 cc J7050 Office 18 51 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OMVOH
  • Lilly USA, LLC $250
$250 — —
STELARA
  • Janssen Biotech, Inc. $210
$210 16 —
Linzess
  • Ironwood Pharmaceuticals, Inc $201
$201 11 —
Sucraid
  • QOL Medical, LLC $198
$198 — —
SKYRIZI
  • AbbVie, Inc. $190
$190 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

405 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Primary Care in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record